FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938921904> ?p ?o ?g. }

• W2938921904 endingPage "230" @default.
• W2938921904 startingPage "225" @default.
• W2938921904 abstract "Background Central venous occlusion may occur in hemodialysis patients, resulting in arm or facial swelling and failure of dialysis access. Endovascular management with balloon angioplasty or stenting has been described, but there are minimal data on the use of covered stents in this pathology. We sought to review a single institution's experience with the use of covered stents for central venous occlusive disease in hemodialysis patients. Methods A retrospective review of all patients undergoing placement of covered stents between April 2014 and December 2016 for central venous occlusive disease to preserve a failing dialysis access was performed. Patients’ records were reviewed to identify demographics, medical comorbidities, operative variables, primary patency rates, and secondary interventions. Results A total of 29 patients were included in the analysis. Viabahn (W.L. Gore and Associates, Flagstaff, AZ) stent grafts were exclusively used in all patients. Technical success rate was 100%. The patients were predominantly female (65.5%), with a mean age of 67.9 ± 12.1 and medical comorbidities of hypertension (86%), diabetes (76%), and tobacco use (7%). The majority (86%) had prior angioplasty and 17 of 29 (59%) patients had previous central venous catheters. The right brachiocephalic vein was the most commonly stented vessel (28%). The median stent length and diameter used were 50 millimeters (range 25–100 millimeters) and 13 millimeters (range: 9–13 millimeters), respectively. The majority of patients (83%) received a single stent, with only 2 patients requiring more than one. Median follow-up was 24 months (range: 6–41 months). Four of 29 (13.8%) patients developed symptomatic stent restenosis requiring secondary intervention, all of which occurred in patients with primary stenosis between 50% and 75%. When compared to the patients without restenosis, longer stents were found to be significantly associated with restenosis (62.5 centimeters, interquartile range [IQR]: 0] vs. 50 centimeter, IQR: 0, P = 0.002). Primary patency rates were 92.9%, 91.7%, and 80.0% at 6, 12, and 24 months respectively. Secondary patency rates were 96.4%, 95.8%, and 93.3% at 6 months, 12 months, and 24 months, respectively. The overall primary patency rate was estimated at 86.2% using Kaplan-Meier analysis at 30.5 months (95% confidence interval: 26.5–34.5 months). Conclusions Covered stent grafts have reasonable primary patency and excellent secondary patency when used for central venous stenosis in dialysis patients. Stent-graft length is associated with poorer long-term patency rates. Central venous occlusion may occur in hemodialysis patients, resulting in arm or facial swelling and failure of dialysis access. Endovascular management with balloon angioplasty or stenting has been described, but there are minimal data on the use of covered stents in this pathology. We sought to review a single institution's experience with the use of covered stents for central venous occlusive disease in hemodialysis patients. A retrospective review of all patients undergoing placement of covered stents between April 2014 and December 2016 for central venous occlusive disease to preserve a failing dialysis access was performed. Patients’ records were reviewed to identify demographics, medical comorbidities, operative variables, primary patency rates, and secondary interventions. A total of 29 patients were included in the analysis. Viabahn (W.L. Gore and Associates, Flagstaff, AZ) stent grafts were exclusively used in all patients. Technical success rate was 100%. The patients were predominantly female (65.5%), with a mean age of 67.9 ± 12.1 and medical comorbidities of hypertension (86%), diabetes (76%), and tobacco use (7%). The majority (86%) had prior angioplasty and 17 of 29 (59%) patients had previous central venous catheters. The right brachiocephalic vein was the most commonly stented vessel (28%). The median stent length and diameter used were 50 millimeters (range 25–100 millimeters) and 13 millimeters (range: 9–13 millimeters), respectively. The majority of patients (83%) received a single stent, with only 2 patients requiring more than one. Median follow-up was 24 months (range: 6–41 months). Four of 29 (13.8%) patients developed symptomatic stent restenosis requiring secondary intervention, all of which occurred in patients with primary stenosis between 50% and 75%. When compared to the patients without restenosis, longer stents were found to be significantly associated with restenosis (62.5 centimeters, interquartile range [IQR]: 0] vs. 50 centimeter, IQR: 0, P = 0.002). Primary patency rates were 92.9%, 91.7%, and 80.0% at 6, 12, and 24 months respectively. Secondary patency rates were 96.4%, 95.8%, and 93.3% at 6 months, 12 months, and 24 months, respectively. The overall primary patency rate was estimated at 86.2% using Kaplan-Meier analysis at 30.5 months (95% confidence interval: 26.5–34.5 months). Covered stent grafts have reasonable primary patency and excellent secondary patency when used for central venous stenosis in dialysis patients. Stent-graft length is associated with poorer long-term patency rates." @default.
• W2938921904 created "2019-04-25" @default.
• W2938921904 creator A5032258787 @default.
• W2938921904 creator A5032744186 @default.
• W2938921904 creator A5045508770 @default.
• W2938921904 creator A5053824220 @default.
• W2938921904 creator A5054982801 @default.
• W2938921904 creator A5080405125 @default.
• W2938921904 date "2019-08-01" @default.
• W2938921904 modified "2023-10-16" @default.
• W2938921904 title "Stent-Graft Length Is Associated with Decreased Patency in Treatment of Central Venous Stenosis in Hemodialysis Patients" @default.
• W2938921904 cites W1969677262 @default.
• W2938921904 cites W1973031258 @default.
• W2938921904 cites W1974098255 @default.
• W2938921904 cites W1974609795 @default.
• W2938921904 cites W1975390687 @default.
• W2938921904 cites W1977757168 @default.
• W2938921904 cites W1989475641 @default.
• W2938921904 cites W2036912228 @default.
• W2938921904 cites W2051899492 @default.
• W2938921904 cites W2057897080 @default.
• W2938921904 cites W2060771275 @default.
• W2938921904 cites W2062757094 @default.
• W2938921904 cites W2086704279 @default.
• W2938921904 cites W2111552163 @default.
• W2938921904 cites W2118861026 @default.
• W2938921904 cites W2124246410 @default.
• W2938921904 cites W2128511362 @default.
• W2938921904 cites W2163522766 @default.
• W2938921904 cites W2231079026 @default.
• W2938921904 cites W2607439144 @default.
• W2938921904 cites W2748192280 @default.
• W2938921904 cites W2793390393 @default.
• W2938921904 doi "https://doi.org/10.1016/j.avsg.2019.01.024" @default.
• W2938921904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31009722" @default.
• W2938921904 hasPublicationYear "2019" @default.
• W2938921904 type Work @default.
• W2938921904 sameAs 2938921904 @default.
• W2938921904 citedByCount "15" @default.
• W2938921904 countsByYear W29389219042020 @default.
• W2938921904 countsByYear W29389219042021 @default.
• W2938921904 countsByYear W29389219042022 @default.
• W2938921904 countsByYear W29389219042023 @default.
• W2938921904 crossrefType "journal-article" @default.
• W2938921904 hasAuthorship W2938921904A5032258787 @default.
• W2938921904 hasAuthorship W2938921904A5032744186 @default.
• W2938921904 hasAuthorship W2938921904A5045508770 @default.
• W2938921904 hasAuthorship W2938921904A5053824220 @default.
• W2938921904 hasAuthorship W2938921904A5054982801 @default.
• W2938921904 hasAuthorship W2938921904A5080405125 @default.
• W2938921904 hasConcept C126838900 @default.
• W2938921904 hasConcept C139059822 @default.
• W2938921904 hasConcept C141071460 @default.
• W2938921904 hasConcept C167135981 @default.
• W2938921904 hasConcept C2778063415 @default.
• W2938921904 hasConcept C2778583881 @default.
• W2938921904 hasConcept C2779978075 @default.
• W2938921904 hasConcept C2780007028 @default.
• W2938921904 hasConcept C2780326628 @default.
• W2938921904 hasConcept C71924100 @default.
• W2938921904 hasConceptScore W2938921904C126838900 @default.
• W2938921904 hasConceptScore W2938921904C139059822 @default.
• W2938921904 hasConceptScore W2938921904C141071460 @default.
• W2938921904 hasConceptScore W2938921904C167135981 @default.
• W2938921904 hasConceptScore W2938921904C2778063415 @default.
• W2938921904 hasConceptScore W2938921904C2778583881 @default.
• W2938921904 hasConceptScore W2938921904C2779978075 @default.
• W2938921904 hasConceptScore W2938921904C2780007028 @default.
• W2938921904 hasConceptScore W2938921904C2780326628 @default.
• W2938921904 hasConceptScore W2938921904C71924100 @default.
• W2938921904 hasLocation W29389219041 @default.
• W2938921904 hasLocation W29389219042 @default.
• W2938921904 hasOpenAccess W2938921904 @default.
• W2938921904 hasPrimaryLocation W29389219041 @default.
• W2938921904 hasRelatedWork W113810927 @default.
• W2938921904 hasRelatedWork W1822146779 @default.
• W2938921904 hasRelatedWork W2046186109 @default.
• W2938921904 hasRelatedWork W2076524943 @default.
• W2938921904 hasRelatedWork W22274899 @default.
• W2938921904 hasRelatedWork W2284817603 @default.
• W2938921904 hasRelatedWork W2376386228 @default.
• W2938921904 hasRelatedWork W2415072310 @default.
• W2938921904 hasRelatedWork W2765513567 @default.
• W2938921904 hasRelatedWork W2418777034 @default.
• W2938921904 hasVolume "59" @default.
• W2938921904 isParatext "false" @default.
• W2938921904 isRetracted "false" @default.
• W2938921904 magId "2938921904" @default.
• W2938921904 workType "article" @default.